Ocular Therapeutix Reports Positive Wet AMD Data

Ocular Therapeutix has released additional positive Week 52 data from its SOL-1 Phase 3 trial for AXPAXLI in wet age-related macular degeneration (AMD). Post-hoc analyses presented at VBS reinforce AXPAXLI's durable efficacy, showing sustained disease control. These results highlight the potential of AXPAXLI as a long-lasting treatment option for wet AMD patients. The extended data further supports the drug's profile for managing this vision-impairing condition.